Dabigatran etexilate containers are demonstrated to decrease of hazard of stroke and fundamental embolism in non-valvular atrial fibrillation in grown-up patients, treatment of profound venous apoplexy and pneumonic embolism in grown-up patients, decrease the gamble of a repeat of profound venous apoplexy and aspiratory embolism in grown-up patients, prophylaxis of profound vein apoplexy and aspiratory embolism in grown-up patients following hip substitution medical procedure. It may not be shown for specific different purposes because of unexpired inclusivities for the RLD for such purposes. 

Dabigatran etexilate cases, 75 mg, 110 mg, and 150 mg have an expected market size of US$ 465 million for a very long time finishing December 2021 as indicated by IQVIA. Alembic has gotten a combined absolute of 162 ANDA endorsements (139 last endorsements and 23 conditional endorsements) from US FDA